Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) — San Antonio, Texas

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) is a clinical research site located in San Antonio, Texas, United States 78229.

Crixeo Health Trust Score: 51/100 (POOR). This profile has not yet been claimed by the site owner.

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) has participated in 1 clinical trials.

Therapeutic areas: Multiple Myeloma Bone Disease.

Sponsors: Novartis Pharmaceuticals.

Sponsor Feasibility Report

Trust Score: 51/100. Verification status: Not yet accredited. Patient reviews: 0. Complaints: 0.

Frequently Asked Questions

What is the Trust Score for Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4)?

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) has a Crixeo Trust Score of 51/100 (POOR). Trust Scores reflect trial volume, sponsor diversity, patient reviews, address verification, and accreditation status.

How many clinical trials has Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) conducted?

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) has 1 clinical trials on record. Their work covers Multiple Myeloma Bone Disease.

Is Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) accredited by Crixeo Health?

Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4) has not yet obtained Crixeo Accreditation. Site owners can claim their profile and apply for accreditation to improve visibility with sponsors and patients.

Can I submit a review or complaint about Cancer Therapy & Research Center / UT Health Science Center InstituteForDrugDevelopment(4)?

Yes. Patients and trial participants can submit reviews and file complaints directly on this profile page. All submissions are reviewed before publication.